Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.

urethra --- onabotulinumtoxinA --- voiding --- therapeutic outcome --- lower urinary tract symptoms --- botulinum toxin --- benign prostatic hyperplasia --- prostatitis --- inflammation --- Botulinum toxin --- chronic prostatitis --- interstitial cystitis --- treatment --- bladder pain --- botulinum toxin A --- predictor --- maximal bladder capacity --- hydrodistention --- urethral sphincter --- urethral sphincter dysfunction --- urodynamics --- drug delivery --- overactive bladder --- painful bladder syndrome --- molecular mechanism --- chronic pelvic pain syndrome --- pelvic pain --- functional urology disorder --- human --- network meta-analysis --- OnabotulinumtoxinA --- peripheral tibial nerve stimulation --- sacral neuromodulation --- bladder --- sensation --- therapy --- pathophysiology --- diabetes mellitus --- mid-urethral sling --- antimuscarinics --- urinary incontinence --- functional urological disorders --- pain --- neurogenic detrusor overactivity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.

Medicine --- urethra --- onabotulinumtoxinA --- voiding --- therapeutic outcome --- lower urinary tract symptoms --- botulinum toxin --- benign prostatic hyperplasia --- prostatitis --- inflammation --- Botulinum toxin --- chronic prostatitis --- interstitial cystitis --- treatment --- bladder pain --- botulinum toxin A --- predictor --- maximal bladder capacity --- hydrodistention --- urethral sphincter --- urethral sphincter dysfunction --- urodynamics --- drug delivery --- overactive bladder --- painful bladder syndrome --- molecular mechanism --- chronic pelvic pain syndrome --- pelvic pain --- functional urology disorder --- human --- network meta-analysis --- OnabotulinumtoxinA --- peripheral tibial nerve stimulation --- sacral neuromodulation --- bladder --- sensation --- therapy --- pathophysiology --- diabetes mellitus --- mid-urethral sling --- antimuscarinics --- urinary incontinence --- functional urological disorders --- pain --- neurogenic detrusor overactivity --- urethra --- onabotulinumtoxinA --- voiding --- therapeutic outcome --- lower urinary tract symptoms --- botulinum toxin --- benign prostatic hyperplasia --- prostatitis --- inflammation --- Botulinum toxin --- chronic prostatitis --- interstitial cystitis --- treatment --- bladder pain --- botulinum toxin A --- predictor --- maximal bladder capacity --- hydrodistention --- urethral sphincter --- urethral sphincter dysfunction --- urodynamics --- drug delivery --- overactive bladder --- painful bladder syndrome --- molecular mechanism --- chronic pelvic pain syndrome --- pelvic pain --- functional urology disorder --- human --- network meta-analysis --- OnabotulinumtoxinA --- peripheral tibial nerve stimulation --- sacral neuromodulation --- bladder --- sensation --- therapy --- pathophysiology --- diabetes mellitus --- mid-urethral sling --- antimuscarinics --- urinary incontinence --- functional urological disorders --- pain --- neurogenic detrusor overactivity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The landscape of minimally invasive urological intervention is changing. A lot of new innovations and technological developments have happened over the last 3 decades. Laparoscopy and robotic surgery have revolutionised kidney and prostate cancer treatment, with more minimally invasive procedures now being carried out than ever before. At the same time, technological advancements and the use of laser have changed the face of endourology. Several new innovative treatments are now commonplace for benign prostate enlargement (BPE). Management of prostate cancer now involves procedures such as robotic prostatectomy, brachytherapy, radiotherapy, cryotherapy and HIFU. Robotic partial nephrectomy and cryotherapy have changed the face of renal cancer. En-bloc resection of bladder cancer is challenging the traditional management of non-muscle invasive bladder cancer and becoming commonplace, while robotic cystectomy is also gaining popularity for muscle invasive bladder cancer. Newer surgical intervention related to BPE includes laser (holmium, thulium and green light), water-based treatment (Rezum, Aquablation) and other minimally invasive procedures such as prostate artery embolisation (PAE) and Urolift. Endourological procedures have incorporated newer laser types and settings such as moses technology, disposable ureteroscopes (URS) and minimisation of percutaneous nephrolithotomy (PCNL) instruments. All these technological innovations and improvements have led to shorter hospital stay, reduced cost, potential reduction in complications and improvement in the quality of life (QoL).

partial nephrectomy --- single site surgery --- sutureless --- CEUS --- contrast-enhanced ultrasound --- renal ultrasound --- image quality --- small renal mass (3–5) --- kidney stones --- metabolic syndrome --- urolithiasis --- nephrolithiasis --- kidney calculi --- diabetes mellitus --- acute kidney injury --- percutaneous nephrolithotomy --- urology --- artificial intelligence --- machine learning --- urinary incontinence --- kidney stone disease --- fertility --- reproductive urology --- renal cell carcinoma --- hydronephrosis --- urinary reflux --- endourology --- pediatric urology --- prostate cancer --- bladder cancer --- nephrostomy --- quality of life --- survival --- decision making --- ureteroscopy --- laser --- RIRS --- Moses --- holmium --- mineral water --- mineral composition --- drinking water --- still water --- sparkling water --- Ho:YAG laser --- thulium fiber laser --- laser fiber --- lithotripsy --- chronic prostatitis --- chronic pelvic pain syndrome --- extracorporeal shockwave therapy --- ESWT --- NIH-CPSI --- EHS --- IIEF-5 --- QoL --- urosepsis --- laser lithotripsy --- predictor factors --- PCNL --- renal tumour --- AI --- TFL